Nimotuzumab, a humanized IgG1 monoclonal antibody targeting EGFR (KD = 0.21 nM), is directed against the extracellular domain of the EGFR blocking the binding to its ligands. It is a potent antitumor agent that has cytolytic effects on target tumors through its ability to induce antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC).